CRVS vs. ONCY, ENLV, AYTU, ORGS, OLMA, TVTX, CMPS, ALT, HRTX, and ATXS
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Oncolytics Biotech (ONCY), Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Orgenesis (ORGS), Olema Pharmaceuticals (OLMA), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Altimmune (ALT), Heron Therapeutics (HRTX), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Oncolytics Biotech presently has a consensus target price of $4.00, suggesting a potential upside of 273.83%. Corvus Pharmaceuticals has a consensus target price of $6.88, suggesting a potential upside of 218.29%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals received 133 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 68.30% of users gave Oncolytics Biotech an outperform vote while only 62.31% of users gave Corvus Pharmaceuticals an outperform vote.
In the previous week, Corvus Pharmaceuticals had 3 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 1 mentions for Oncolytics Biotech. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Oncolytics Biotech's score of 0.97 indicating that Oncolytics Biotech is being referred to more favorably in the media.
6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oncolytics Biotech's return on equity of -59.96% beat Corvus Pharmaceuticals' return on equity.
Oncolytics Biotech has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Summary
Oncolytics Biotech beats Corvus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
